Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2021.460 | Profiling of Serum Protein Biomarkers in Psoriatic Arthritis–Associated Disease Activity Assessment and Bone Damage |
Prof. TAM Lai Shan 譚麗珊 |
| 2021.315 | Axial involvement in patients with Psoriatic Arthritis in Hong Kong – a cross-sectional pilot study |
Prof. TAM Lai Shan 譚麗珊 |
| 2023.189 | Survey of cardiovascular disease Risk Factors in Psoriatic Arthritis | Prof. TAM Lai Shan |
| 2023.127 | Machine learning models to quantify and predict radiographic joint damage in rheumatoid arthritis |
Prof. TAM Lai Shan Lai Shan TAM |
| 2023.181 | Anti-inflammatory mechanisms of immune-adipose-related Meteorin-like protein (METRNL) in Systemic Lupus Erythematosus | Dr. TAM Lai Shan |
| 2020.519 | Cardiovascular events in axial spondyloarthritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.516 | CUHK Rheumatology Research Centre Imaging Database of Rheumatic Diseases |
Prof. TAM Lai Shan 譚麗珊 |
| 2022.686 | Bone Erosion Volume Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as predictor of disability in patients with psoriatic arthritis | Prof. TAM Lai Shan |
| 2023.051 | Discovering new post-translational modification patterns for the early diagnosis of rheumatoid arthritis | Prof. TAM Lai Shan |
| 2020.530 | 5-Year Cardiovascular Event Risk in Early Rheumatoid Arthritis Patients who received Treat-to-Target Management: a population-based cohort study |
Prof. TAM Lai Shan 譚麗珊 |
| 2021.187 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Dapirolizumab pegol in Study Participants with Moderately to Severely Active Systemic Lupus Erythematosus |
Prof. TAM Lai Shan 譚麗珊 教授 |
| 2021.568 | A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease |
Prof. TAM Lai Shan 譚麗珊 |
| 2021.343 | AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS COHORT (AXIS) a joint ASAS-GRAPPA project |
Prof. TAM Lai Shan 譚麗珊 |
| 2014.343 | Adaptation and validation of the Ankylosing Spondylitis Quality of Life (ASQOL) and Psoriatic Arthritis Quality of Life (PsAQOL) questionnaires in Hong Kong | Prof. TAM Lai Shan |
| 2015.697 | Freely circulating microRNAs as biomarkers for fracture and bone loss in female patients with systemic lupus erythematosus on long-term glucocorticoid therapy |
Prof. TAM Lai Shan 譚麗珊 |
| 2015.664 | A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs |
Prof. TAM Lai Shan 譚麗珊 |
| 2015.214 | Prevalence and risk factors for osteoporosis in patients with ankylosing spondylitis in Hong Kong: a cross-sectional cohort study |
Dr. TAM Lai Shan 譚麗珊 |
| 2017.389 | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) – SELECT – PsA 1 | Prof. TAM Lai Shan |
| 2013.451 | Immunopathological roles of the novel inflammatory cytokine interleukin-36 in the patients with systemic lupus erythematous | Professor TAM Lai Shan |
| 2017.261 | The impact of nurse-led programme with and without statin treatment base on traditional cardiovascular risk score or carotid ultrasound on addressing cardiovascular risk in patients with arthritis: a prospective, multicentre, randomised, controlled trial | Prof. TAM Lai Shan |
| 2016.551 | A Randomized Open-label Study to Evaluate the Efficacy and Safety of Tacrolimus and Corticosteroids in Comparison with Mycophenolate Mofetil and Corticosteroids in Subjects with Class III/IV±V Lupus Nephritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2014.387 | Coronary atherosclerosis in psoriatic arthritis | Prof. TAM Lai Shan |
| 2016.450 | Cost Effectiveness Analysis of Biologic Therapies for the Treatment of Rheumatoid Arthritis in Hong Kong |
Prof. TAM Lai Shan 譚麗珊教授 |
| 2016.451 | Prevention of metacarpophalangeal joints structure damage in patients with psoriatic arthritis using secukinumab |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.366 | MicroRNAs as biomarkers for predicting the effect of anti-TNF and anti-IL6 in changes of bone erosions in rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2015.065 | Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis | Prof. TAM Lai Shan |
| 2016.037 | Identification and validation of microRNAs associated with inflammation detected by magnetic resonance imaging in patients with early rheumatoid arthritis. |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.431 | Effect of RANKL inhibition on healing of bone erosion in rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.390 | Assessment of structure changes after 4 years on the second and third metacarpophalangeal joint and distal radius in patients with psoriatic arthritis – a follow-up study using High-resolution peripheral quantitative CT (HR-pQCT) |
Prof. TAM Lai Shan 譚麗珊 |
| 2017.239 | The Hong Kong Psoriatic Arthritis Screening program | Prof. TAM Lai Shan |
| 2013.300 | Immunopathological roles of the novel anti-inflammatory cytokine interleukin-35 in the patients with systemic lupus erythematous | Professor TAM Lai Shan |
| 2017.146 | Circulating microRNAs as biomarkers for predicting the early development, repair and progression of bone erosions in early rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2014.052 | Advanced 3-D Bioimaging Technology to improve vertebral fracture prediction in patients with glucocorticoid-induced osteoporosis | Prof. TAM Lai Shan |
| 2016.359 | A double-blind, randomised, placebo-controlled trial evaluating the effect of BI 655064 administered as sub-cutaneous injections, on renal response after one year of treatment, in patients with active lupus nephritis |
Prof. TAM Lai Shan 譚麗珊教授 |
| 2015.334 | Characterization of the potential role of interleukin-36 (IL-36) in regulating protective and pathogenic B cells in systemic lupus erythematosus |
Dr. TAM Lai Shan 譚麗珊 |
| 2017.295 | The long term renal outcome of biopsy proven paediatric lupus nephritis - a comparison of local and overseas cohort |
Prof. TAM Lai Shan 譚麗珊 |
| 2013.469 | The Clinical Rheumatology Systematic Treat-to-target in Asia Leadership (CRYSTAL) Project | Prof. TAM Lai Shan |
| 2016.533 | A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.540 | A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). |
Dr. TAM Lai Shan 譚麗珊 |
| 2018.144 | Bone Microarchitecture Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as predictor of fracture risk in patients with glucocorticoid-induced osteoporosis |
Prof. TAM Lai Shan 譚麗珊 |
| 2017.700 | Circulating microRNA 99b as biomarker for predicting the early development, repair and progression of bone erosions in early rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.063 | Effects of tight-control strategy with rosuvastatin on progression of subclinical carotid and coronary atherosclerosis in psoriatic arthritis- a prospective cohort study |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.129 | Vascular effects of achieving low disease activity in axial spondyloarthritis - a 2-year prospective cohort study |
Prof. TAM Lai Shan 譚麗珊 |
| 2018.225 | The APLAR Spondyloarthritis (SpA) Registry |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.180 | The microbiome study in psoriasis and psoriatic arthropathy patients in Hong Kong |
Prof. TAM Lai Shan 譚麗珊 |
| 2017.446 | A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2017.605 | Evaluation of molecular and cellular dysregulation in systemic lupus erythematosus | Prof. TAM Lai Shan |
| 2019.650 | Effects of tight-control strategy with and without rosuvastatin on progression of subclinical coronary and carotid atherosclerosis in psoriatic arthritis- a randomized placebo-controlled study |
Prof. TAM Lai Shan 譚麗珊 |
| 2017.633 | An exploratory maintenance trial evaluating the effect of BI 655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment outside of 1293.10 |
Prof. TAM Lai Shan 譚麗珊教授 |
| 2019.401 | Immunological role of the ILC2-B lymphocyte regulatory axis in systemic lupus erythematosus |
Prof. TAM Lai Shan 譚麗珊 |
Page 64 of 268.